Repligen (RGEN) Q1 2025 Earnings Call April 29, 2025 01:53 PM ET Speaker0 Good day, ladies and gentlemen, and welcome to Repligen Corporation's First Quarter of twenty twenty five Earnings Conference Call. My name is Dovan, and I will be your coordinator. All participants will be in the listen only mode. Please note that there will be a question and answer session following the company's formal remarks. The company would like to note that there will be a limited timeframe for Q and A, and as such, managemen ...

Core Viewpoint - Repligen (RGEN) reported quarterly earnings of $0.39 per share, exceeding the Zacks Consensus Estimate of $0.35 per share, and showing an increase from $0.28 per share a year ago, indicating a positive earnings surprise of 11.43% [1][2] Financial Performance - The company achieved revenues of $169.17 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.85% and up from $151.35 million year-over-year [2] - Over the last four quarters, Repligen has exceeded consensus EPS estimates three times and topped revenue estimates two times [2] Stock Performance and Outlook - Repligen shares have declined approximately 0.2% since the beginning of the year, contrasting with the S&P 500's decline of 6% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is $0.42 on revenues of $174.55 million, and for the current fiscal year, it is $1.69 on revenues of $701.98 million [7] - The estimate revisions trend for Repligen is currently mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Repligen belongs, is currently ranked in the top 31% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

WALTHAM, Mass., April 29, 2025 -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2025, covering the three-month period ended March 31, 2025. The company is also providing updated financial guidance for the full year 2025. Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2025 Financial Results Olivier Loeillo ...

Revenue of $169 million, year-over-year increase of 10% as reported and 14% organic non-COVID growthOrders increased sequentially and high-teens year-over-year Adjusted operating income increased 72% year-over-year Reiterates 2025 full year organic revenue guidance of 9.5% - 13.5% WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2025, coveri ...

Webcast and Conference Call to Be Held Tuesday, April 29, 2025, at 8:30 a.m. ETWALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2025 financial results on Tuesday, April 29, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- month reporting period ended March 31, 2025. The conferen ...

Core Insights - Repligen Corporation has appointed Jacob Johnson as Vice President of Investor Relations, who will lead the engagement with the investment community [1][2] - Jacob Johnson has a strong background in the life sciences tools and pharma services sector, having covered Repligen as a research analyst since 2019 [2] - The company expresses gratitude towards outgoing Vice President Sondra Newman for her contributions since 2012 [2] Company Overview - Repligen Corporation is a global life sciences company focused on developing and commercializing innovative bioprocessing technologies for manufacturing biological drugs [3] - The company serves biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide, with a focus on areas such as Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins [3] - Repligen's headquarters are located in Waltham, Massachusetts, with manufacturing sites primarily in the U.S. and additional key locations in Estonia, France, Germany, Ireland, the Netherlands, and Sweden [3]

WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the investor relations team's engagement with the investment community, reporting to the company's Chief Financial Officer, Jason K. Garland. Most recently, Mr. Johnson served as Managing Director, Research Analyst at Stephens Inc., where he followed the life sciences tools and pharma services sector. ...

Repligen (RGEN) shares soared 3.7% in the last trading session to close at $116.11. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 28.1% loss over the past four weeks.Positive investor sentiment for Repligen's various business segments might have driven the recent share price rally. The company recently purchased 908 Devices’ desktop portfolio of four devices for bioprocessing process analytical technology applications to improv ...

I assigned a ‘buy’ rating to Repligen ( RGEN ) in July 2024, highlighting its strong filtration and weak growth in China. Since then, the stock price has surged by more than 14%. I believe Repligen’s business will gradually recover in FY25, supported byMore than 15 years of professional investment experience in global equities across all sectors. My investment style is fundamental, bottom-up, long-term, and quality growth-oriented. I am seeking companies specializing in niche markets, with strong growth pot ...

Financial Performance - Total revenue for 2024 was $634.4 million, a 0.3% increase from $632.4 million in 2023[283]. - Product revenue increased by $2.2 million, or 0.3%, in 2024, driven by a $31.6 million increase in Filtration product revenue, offset by a $29.0 million decrease in Proteins product revenue[286]. - Total costs and operating expenses for 2024 were $669.6 million, an increase of $84.9 million, or 14.5%, compared to $584.7 million in 2023[288]. - Gross margin decreased to 43.3% in 2024 from 44.0% in 2023, primarily due to increased restructuring costs[291]. - The company recorded an income tax benefit of $1.5 million in 2024, with an effective tax rate of 5.6%, down from 37.2% in 2023[305]. Debt and Financing - The company issued $600.0 million aggregate principal amount of 1.00% Convertible Senior Notes due 2028 in December 2023[270]. - The carrying value of the 2023 Notes was $525.6 million as of December 31, 2024[272]. - The company recognized a $12.7 million loss on extinguishment of debt for the year ended December 31, 2023[271]. - Interest expense surged by $18.2 million, or 728.2%, in 2024, primarily due to new debt issuance and related costs[299]. - In 2023, cash provided by financing activities totaled $249.0 million, including $290.1 million from the issuance of the 2023 Notes[318]. Inventory and Cost Management - The company recorded $36.0 million in inventory adjustments in 2024 due to discontinuation of certain product SKUs and proactive material procurement during the pandemic[260]. - Cost of goods sold rose by $5.9 million, or 1.7%, in 2024, including $12.5 million of inventory adjustments and $6.1 million related to closed manufacturing facilities[289]. - The company has successfully implemented price increases and productivity improvements to mitigate supply chain disruptions and inflation[252]. Research and Development - Research and development expenses increased by $0.5 million, or 1.1%, in 2024, primarily due to a $1.8 million rise in employee-related costs[293]. - R&D expenses for expanding protein product offerings were $3.1 million in 2024, $3.8 million in 2023, and $2.6 million in 2022[294]. - The company plans to continue investing in its bioprocessing business and R&D activities for new products[322]. Acquisitions and Investments - The company acquired Tantti for $54.8 million in cash in 2024, with an obligation for up to $54.5 million in contingent earnout payments over three years[308]. - Investing activities consumed $86.4 million in 2024, primarily due to the acquisition of Tantti and capital expenditures of $29.9 million[315]. Cash Flow and Liquidity - Cash and cash equivalents increased to $757.4 million as of December 31, 2024, compared to $751.3 million at the end of 2023[307]. - Cash provided by operating activities was $175.4 million in 2024, reflecting a net loss of $25.5 million and non-cash charges totaling $140.0 million[313]. Foreign Currency and Exchange Rates - The company’s revenue is significantly influenced by foreign currency exchange rates due to its global presence[251]. - 37.0% of total revenues were denominated in foreign currencies during 2024, compared to 37.9% in 2023[331]. - The U.S. dollar strengthened against the Swedish krona by 9%, the Euro by 6%, and the British pound by 2% in 2024[320]. - The company uses foreign exchange forward contracts to hedge against currency exchange rate fluctuations[332]. Contingent Consideration and Fair Value - The fair value of contingent consideration obligations for the year ended December 31, 2024 had a net change of $3.2 million primarily related to the acquisition of Avitide, Inc.[262]. - Contingent consideration adjustments for 2024 resulted in a fair value increase of $3.2 million, compared to decreases of $30.6 million in 2023 and $28.7 million in 2022[297]. Stock-Based Compensation - Stock-based compensation expense for 2024 was $48.1 million, compared to $25.6 million in 2023[277]. - As of December 31, 2024, there was $56.5 million of total unrecognized compensation cost related to unvested share-based awards[278]. - SG&A expenses increased by $44.8 million, or 20.5%, in 2024 compared to 2023, primarily due to $22.4 million related to the former CEO's equity awards modification[296].